Should the UK trial faster routes for new medicines with the pharma industry?

A clear if not overwhelming win for trialling faster medicine approvals alongside the pharma industry, 33 votes to 23, an 18-point margin from 56 registered voters. This was not the rout the topline suggests once the internals are unpicked.

The story here is gender, not age. Men voted yes by 65% to 35% (24-13), while women went the other way, 36% yes to 64% no (4-7) — a near-mirror inversion that did most of the work in shaping the overall result. Age, by contrast, produced no clean fracture: 25-34s split dead even at 7-7, while 35-44s were the most enthusiastic backers at 71%, and every other bracket clustered in the high-50s to 60% yes.

The pattern echoes a familiar tension in health policy debates about industry co-design — enthusiasm for speed and innovation running up against caution about access, pricing and whose interests a "trade deal" pilot really serves, with patient groups on the taskforce doing little to close that gap here. It is the kind of split that tends to appear whenever a reform bundles efficiency gains with private-sector involvement in the NHS-adjacent space.

For a scheme co-designed with patient groups, it is notable that women — often the more frequent users of medicines and health services — proved the most sceptical bloc in the room.